A new drug, tavapadon, has emerged as a promising treatment for Parkinson's disease, particularly for patients already using levodopa. In a pivotal study, tavapadon effectively alleviated motor fluctuations, such as tremors and stiffness, without the common adverse effects seen with levodopa. Unlike levodopa, which can lead to side issues like hallucinations and sleep disorders, tavapadon targets D1/D5 receptors mimicking dopamine. The research demonstrated that patients experienced more 'on time' and less 'off time' while on tavapadon. While results are promising, further study is needed to confirm these effects long-term.
"It provides patients with another option to alleviate their motor fluctuations that are commonly experienced with levodopa (the best drug we have so far in Parkinson's) in the moderate to advanced stages of the disorder," Fernandez told Fox News Digital.
"This global, multi-center, pivotal trial showed that patients placed on tavapadon had significantly more 'on time' and less 'off time' compared to those who received placebo - and that the drug was well-tolerated by patients."
Collection
[
|
...
]